查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1496004

全球生物製品市场：2024-2029 年预测

Global Biologics Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 121 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

生物製品市场预计将从 2022 年的 4,021.82 亿美元成长到 2029 年的 7,611.39 亿美元，复合年增长率为 9.54%。

市场的长期前景取决于市场参与企业不断增加的财务投资、癌症和自体免疫疾病等慢性疾病的出现以及对先进技术治疗方法日益增长的热情。据世界卫生组织 (WHO) 称，癌症是全球最常见的死亡原因，预计到 2022 年将有 970 万人受到该疾病的影响。肥胖、水果和蔬菜摄取量低、缺乏体力活动以及烟草和酒精消费的增加预计将在未来几年增加癌症病例。

全球人口老化趋势也将产生对生物製药的需求。研究和开发的资本投入也是预期对市场成长产生正面影响的因素之一。然而，单株抗体、重组 DNA 技术、治疗性蛋白质和疫苗等新型治疗方案的兴起正在推动生物技术和製药公司生产生物製药。此外，现在的公司非常关注研发和製造设施。

  • 慢性病的流行、对学名药的需求增加以及疫苗产量的增加

在糖尿病、气喘、癌症和自体免疫疾病等慢性疾病增加的强力支持下，该市场正在不断增长。大量的慢性病意味着对生物药物的需求增加。同时，对抗登革热、疟疾和基孔肯雅热的疫苗接种激增正在推动生物製品市场的成长。此外，人口成长正在减少印度、中国和美国等全球主要参与者对学名药的需求。

许多国家正在共同开发可用于治疗各种疾病的疫苗和医疗设备，例如犬藏红花。此外，随着主要企业增加对综合设施的持续投资，市场成长预计将进一步增加。例如，2024年1月，艾伯维将投资2.23亿美元扩大新加坡工厂，以扩大其生物製剂生产设施。这项重大投资将重点用于将生物製品原料产能提高 24,000 公升，并创造 100 多个新工作机会。除了生产现有产品外，还将为免疫学和肿瘤学领域的下一代产品的生产做出贡献。

  • 生物製品市场按应用细分为肿瘤学、神经学、循环系统、血液学、自体免疫疾病、感染疾病等。

全球癌症死亡率的上升和癌症研发活动是显示该市场未来扩张潜力的两个因素。此外，根据癌症的类型，生物製药疗法比传统的放射线治疗或化疗具有更少的副作用，这也促进了癌症领域生物製药市场的开拓趋势。此外，治疗多种癌症的新生物疗法的出现将为多种癌症提供治疗选择。因此，这将促进生物製药市场肿瘤领域的开拓。

例如，美国癌症协会发表的一篇论文估计，2023年1月，美国将新增1,958,310例癌症病例，609,820例癌症相关死亡病例。随着世界各地新癌症患者和癌症死亡人数迅速增加，全球肿瘤学活动可能活性化。除此之外，世界各地还有许多生物疗法用于检测和治疗癌症，包括免疫疗法、基因疗法、过继性细胞移植和化疗。例如，免疫疗法等生物疗法可用于治疗多种癌症，包括最常见的肺癌、乳癌和皮肤癌。

此外，免疫疗法并没有使用有毒化学物质来消除癌细胞和非癌细胞，这就是化疗的概念。在约翰霍普金斯大学的第二个案例研究中，梅克尔细胞癌（一种侵袭性皮肤癌）透过免疫疗法得到了更有效的治疗。结果，存活率提高了。此外，2022年2月，CRI发布了针对免疫PD1/PDL1查核点的临床药物开发的全球现况。

例如，2023年，Astra Zeneca在其临床试验增刊中发表了报导，其中重点介绍了目前正在试验中效果最好的一些药物。 Tagrisso（医学术语： Osimertinib）是一种高效能抗癌药物，作为辅助治疗形式用于治疗肺癌。该药物被归类为 EGFR 抑制剂，其特性使其有别于其他药物。凭藉其高度选择性和不可逆的作用机制，Tagrisso 精确靶向具有 EGFR 突变的癌细胞，并与其建立持续的联繫，最终抑制其增殖。这些重大发展和肿瘤生物製药的好处将导致生物製药在全球市场的市场占有率。

市场挑战

  • 新治疗方法的市场开拓成本不断上升，限制了生物製剂市场的成长。

由于复杂的开发和製造流程、漫长的临床试验以及政府当局的严格监管，开发和製造生物製药的成本高昂。这些因素会影响患者的就诊并导致医疗保健投资增加。

  • 生物製剂的寿命短也阻碍了生物製剂市场的成长。

各种生物製品在环境中的持久性比传统药物低，因此需要安全储存并防止作为废弃物处置。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关利益者的主要利益

第二章调查方法

  • 研究设计
  • 调查过程

第三章执行摘要

  • 主要发现

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第五章全球生物製品市场：依产品类型

  • 介绍
  • 单株抗体
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 疫苗
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 重组蛋白
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 基因治疗
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 基于细胞的生物製剂
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 其他的
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力

第六章全球生物製品市场：依应用分类

  • 介绍
  • 肿瘤学
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 神经病学
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 心臟病学
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 血液学
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 自体免疫疾病
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 感染疾病
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 其他的
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力

第七章 全球生物製品市场：依地区划分

  • 介绍
  • 北美洲
    • 依产品类型
    • 按用途
    • 按国家/地区
  • 南美洲
    • 依产品类型
    • 按用途
    • 按国家/地区
  • 欧洲
    • 依产品类型
    • 按用途
    • 按国家/地区
  • 中东/非洲
    • 依产品类型
    • 按用途
    • 按国家/地区
  • 亚太地区
    • 依产品类型
    • 按用途
    • 按国家/地区

第八章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第九章 公司简介

  • Hoffmann-La Roche AG
  • Amgen Inc.
  • AbbVie Inc.
  • Novo Nordisk A/S
  • Johnson & Johnson
  • Takeda Pharmaceutical Company
  • Alexion Pharmaceuticals
  • Samsung Biologics
  • UCB SA
  • Merck & Co. Inc
  • Eli Lilly and Company
  • Sanofi SA
简介目录
Product Code: KSI061611837

The global biologics market is projected to grow at a CAGR of 9.54% to reach US$761.139 billion by 2029, from US$402.182 billion in 2022.

The long-term outlook of the market is determined by the increasing financial investments of the dominant market participants, the advent of chronic diseases like cancer and autoimmune illnesses, and the increasing enthusiasm for technologically advanced therapies. According to the World Health Organization, the most commonly detected cause of death worldwide is cancer and its consequences were recorded as nearly 9.7 million in 2022. Expanding tobacco and alcohol intake along with obesity, low levels of fruit and vegetable intake, and the lack of physical exercise are expected to increase the cases of cancer in the coming years.

The worldwide trend of an aged population is also supposed to create the need for biological products. Besides, capital injections in research and development are among the factors expected to have a positive influence on market growth. However, a growing number of novel treatment options like monoclonal antibodies, recombinant-DNA technology, therapeutic proteins, and vaccines driving the biotechnological and pharmaceutical companies towards the production of biologics. Also, companies have recently given a lot of attention to research and development or manufacturing facilities.

  • Rising prevalence of chronic disease & Growing demand for generic drugs along with an increase in the production of vaccines

The market is growing with strong support from the rising of chronic diseases such as diabetes, asthma, cancer, auto-immune disease, and so on. Huge numbers of chronic diseases mean increasing demand for biological medicines. On the other side, surging vaccination production for the entire globe to fight dengue, malaria, and chikungunya is propelling the growth of the global biologics market. In addition, the enlarged population also lowers the demand for generic drugs in major global players like India, China, and the US.

Many countries work together for a vaccine and medical devices that could be utilized in the cure of various diseases like caner. Further, greater investments in the ongoing integrated facilities for the key players will add to the market growth. For instance, in January 2024 AbbVie is expanding its biologics manufacturing facilities via a substantial $223 million investment in expansion of its Singapore plant. This meaningful investment will concentrate on the increase of the capacity by 24 thousand liters of biologics drug materials and the creation of more than 100 new job positions. Apart from the production of the current items, they will also be instrumental in the production of next-generation products in the fields of immunology and oncology.

  • Based on application, the global biologics market is segmented into oncology, neurology, cardiology, hematology, autoimmune diseases, infectious diseases, and others.

The worldwide rise in cancer mortality rates and cancer research and development activities are two factors that show a likelihood for the future increase of this market. Further, biologics treatment demonstrates fewer side effects than conventional radiotherapy/chemotherapy for some cancer types which also plays a part in the development trend of the biologics market in the oncology sector. Moreover, as new biologic therapeutics become available for treating more than one type of cancer, it will provide treatment options for multiple types of cancer. Therefore, this will drive the oncology segment of the biologic drugs market's development.

For instance, according to the American Cancer Society published article, in January 2023 it is evaluated that in the year 2023, there will be 1,958, 310 new cases of cancer and 609, 820 cancer-associated fatalities in the United States region. These incredible numbers surge in new cases and people who die of cancers worldwide will possibly lead to the global rise of activities in oncology. In addition to these, there are many other biological treatments including immunotherapy, gene therapy, adoptive cell transfer, bio-chemotherapy, and so on to discover and treat cancers around the globe. For example, such biological treatment as immunotherapy can be used for the treatment of many different cancers including lung, breast, and skin cancer, the most common types.

Furthermore, immunotherapy does not annihilate both cancer and non-cancer cells by toxic chemicals, which is the concept of chemotherapy. The second case study according to Johns Hopkins University, Merkel cell carcinoma - an aggressive type of skin cancer - was treated more effectively with immunotherapy. It resulted in better survival rates. Also, CRI came out in public in February 2022 with the global landscape of clinical drug development targeting immune PD1/PDL1 checkpoints.

For instance, in 2023 AstraZeneca published an article on clinical trials appendix in which there are some medications that are under trial and showing the best results as the output Tagrisso, or osimertinib in medical terminology, is a very powerful anticancer drug for lung cancer treatment, as a form of adjuvant therapy. This drug is classified as an EGFR inhibitor which is defined by its having a property that is distinguishable from other drugs. By having a highly selective and irreversible mechanism of action Tagrisso aims precisely at the cancer cells with EGFR mutations and establishes a continuous connection with them, thus, ultimately, inhibiting their proliferation. These key developments, as well as the benefits contributed by biologics in oncology, will bring the market share of biologics in the oncology segment to the global market.

Market Challenges

  • Surge in the cost of development of new treatment options curbs the global biologics market growth.

The creation and production of biologics is costly due to the intricate process in the development and manufacturing process, prolonged clinical trials, and strict regulations by government authorities. These factors influence the patient's access and incur more healthcare investments.

  • The short life span of biologics hinders the global biologics market growth.

The various biologics don't sustain more in the environment as compared to traditional or conventional drugs these biologics need to be taken care of in the inventory by preserving safely by preventing the material from being disposed of as waste.

Key Developments

  • In March 2023: Sanofi a renowned pharmaceuticals and healthcare company has initiated its first biological drug called Dupixent which is specifically designed for the treatment of COPD. This drug inhibits good results during the various primary trials which help in the management process of COPD.

Market Segmentation

BY PRODUCT TYPE

  • Monoclonal Antibodies
  • Vaccines
  • Recombinant Proteins
  • Gene Therapy
  • Cellular-based Biologics
  • Others

BY APPLICATION

  • Oncology
  • Neurology
  • Cardiology
  • Hematology
  • Autoimmune Diseases
  • Infectious Diseases
  • Others

BY GEOGRAPHY

  • North America
  • U.S
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • South Africa
  • Asia Pacific
  • China
  • Japan
  • India
  • Indonesia
  • South Korea
  • Taiwan
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL BIOLOGICS MARKET BY PRODUCT TYPE

  • 5.1. Introduction
  • 5.2. Monoclonal Antibodies
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Vaccines
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness
  • 5.4. Recombinant Proteins
    • 5.4.1. Market Opportunities and Trends
    • 5.4.2. Growth Prospects
    • 5.4.3. Geographic Lucrativeness
  • 5.5. Gene Therapy
    • 5.5.1. Market Opportunities and Trends
    • 5.5.2. Growth Prospects
    • 5.5.3. Geographic Lucrativeness
  • 5.6. Cellular-based Biologics
    • 5.6.1. Market Opportunities and Trends
    • 5.6.2. Growth Prospects
    • 5.6.3. Geographic Lucrativeness
  • 5.7. Others
    • 5.7.1. Market Opportunities and Trends
    • 5.7.2. Growth Prospects
    • 5.7.3. Geographic Lucrativeness

6. GLOBAL BIOLOGICS MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Oncology
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Neurology
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. Cardiology
    • 6.4.1. Market Opportunities and Trends
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness
  • 6.5. Hematology
    • 6.5.1. Market Opportunities and Trends
    • 6.5.2. Growth Prospects
    • 6.5.3. Geographic Lucrativeness
  • 6.6. Autoimmune Diseases
    • 6.6.1. Market Opportunities and Trends
    • 6.6.2. Growth Prospects
    • 6.6.3. Geographic Lucrativeness
  • 6.7. Infectious Diseases
    • 6.7.1. Market Opportunities and Trends
    • 6.7.2. Growth Prospects
    • 6.7.3. Geographic Lucrativeness
  • 6.8. Others
    • 6.8.1. Market Opportunities and Trends
    • 6.8.2. Growth Prospects
    • 6.8.3. Geographic Lucrativeness

7. GLOBAL BIOLOGICS MARKET BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. By Product Type
    • 7.2.2. By Application
    • 7.2.3. By Country
      • 7.2.3.1. U.S.
        • 7.2.3.1.1. Market Opportunities and Trends
        • 7.2.3.1.2. Growth Prospects
      • 7.2.3.2. Canada
        • 7.2.3.2.1. Market Opportunities and Trends
        • 7.2.3.2.2. Growth Prospects
      • 7.2.3.3. Mexico
        • 7.2.3.3.1. Market Opportunities and Trends
        • 7.2.3.3.2. Growth Prospects
  • 7.3. South America
    • 7.3.1. By Product Type
    • 7.3.2. By Application
    • 7.3.3. By Country
      • 7.3.3.1. Brazil
        • 7.3.3.1.1. Market Opportunities and Trends
        • 7.3.3.1.2. Growth Prospects
      • 7.3.3.2. Argentina
        • 7.3.3.2.1. Market Opportunities and Trends
        • 7.3.3.2.2. Growth Prospects
      • 7.3.3.3. Others
        • 7.3.3.3.1. Market Opportunities and Trends
        • 7.3.3.3.2. Growth Prospects
  • 7.4. Europe
    • 7.4.1. By Product Type
    • 7.4.2. By Application
    • 7.4.3. By Country
      • 7.4.3.1. United Kingdom
        • 7.4.3.1.1. Market Opportunities and Trends
        • 7.4.3.1.2. Growth Prospects
      • 7.4.3.2. Germany
        • 7.4.3.2.1. Market Opportunities and Trends
        • 7.4.3.2.2. Growth Prospects
      • 7.4.3.3. France
        • 7.4.3.3.1. Market Opportunities and Trends
        • 7.4.3.3.2. Growth Prospects
      • 7.4.3.4. Italy
        • 7.4.3.4.1. Market Opportunities and Trends
        • 7.4.3.4.2. Growth Prospects
      • 7.4.3.5. Spain
        • 7.4.3.5.1. Market Opportunities and Trends
        • 7.4.3.5.2. Growth Prospects
      • 7.4.3.6. Others
        • 7.4.3.6.1. Market Opportunities and Trends
        • 7.4.3.6.2. Growth Prospects
  • 7.5. Middle East and Africa
    • 7.5.1. By Product Type
    • 7.5.2. By Application
    • 7.5.3. By Country
      • 7.5.3.1. Saudi Arabia
        • 7.5.3.1.1. Market Opportunities and Trends
        • 7.5.3.1.2. Growth Prospects
      • 7.5.3.2. UAE
        • 7.5.3.2.1. Market Opportunities and Trends
        • 7.5.3.2.2. Growth Prospects
      • 7.5.3.3. South Africa
        • 7.5.3.3.1. Market Opportunities and Trends
        • 7.5.3.3.2. Growth Prospects
  • 7.6. Asia Pacific
    • 7.6.1. By Product Type
    • 7.6.2. By Application
    • 7.6.3. By Country
      • 7.6.3.1. China
        • 7.6.3.1.1. Market Opportunities and Trends
        • 7.6.3.1.2. Growth Prospects
      • 7.6.3.2. Japan
        • 7.6.3.2.1. Market Opportunities and Trends
        • 7.6.3.2.2. Growth Prospects
      • 7.6.3.3. India
        • 7.6.3.3.1. Market Opportunities and Trends
        • 7.6.3.3.2. Growth Prospects
      • 7.6.3.4. Indonesia
        • 7.6.3.4.1. Market Opportunities and Trends
        • 7.6.3.4.2. Growth Prospects
      • 7.6.3.5. South Korea
        • 7.6.3.5.1. Market Opportunities and Trends
        • 7.6.3.5.2. Growth Prospects
      • 7.6.3.6. Taiwan
        • 7.6.3.6.1. Market Opportunities and Trends
        • 7.6.3.6.2. Growth Prospects
      • 7.6.3.7. Thailand
        • 7.6.3.7.1. Market Opportunities and Trends
        • 7.6.3.7.2. Growth Prospects
      • 7.6.3.8. Others
        • 7.6.3.8.1. Market Opportunities and Trends
        • 7.6.3.8.2. Growth Prospects

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Market Share Analysis
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Competitive Dashboard

9. COMPANY PROFILES

  • 9.1. Hoffmann-La Roche AG
  • 9.2. Amgen Inc.
  • 9.3. AbbVie Inc.
  • 9.4. Novo Nordisk A/S
  • 9.5. Johnson & Johnson
  • 9.6. Takeda Pharmaceutical Company
  • 9.7. Alexion Pharmaceuticals
  • 9.8. Samsung Biologics
  • 9.9. UCB S.A.
  • 9.10. Merck & Co. Inc
  • 9.11. Eli Lilly and Company
  • 9.12. Sanofi SA